Dr Reddy's Laboratories Ltd

Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1364.9, up 1.02% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.28% on the day, quoting at 25069.95. The Sensex is at 82276.06, down 0.29%. Dr Reddys Laboratories Ltd has gained around 13.07% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 4.05% in last one month and is currently quoting at 22057.15, up 0.76% on the day. The volume in the stock stood at 11.71 lakh shares today, compared to the daily average of 17.74 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1361.1, up 0.71% on the day. Dr Reddys Laboratories Ltd is up 11.95% in last one year as compared to a 7.14% jump in NIFTY and a 12.03% jump in the Nifty Pharma index.The PE of the stock is 21.07 based on TTM earnings ending March 25.Powered by Capital Market - Live

Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1321.8, up 0.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.46% on the day, quoting at 25117.25. The Sensex is at 82511.15, up 0.39%. Dr Reddys Laboratories Ltd has risen around 10.56% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has risen around 3.24% in last one month and is currently quoting at 21684.4, up 0.47% on the day. The volume in the stock stood at 9.1 lakh shares today, compared to the daily average of 19.37 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1320.2, up 0.24% on the day. Dr Reddys Laboratories Ltd is up 8.24% in last one year as compared to a 7.99% spurt in NIFTY and a 10.18% spurt in the Nifty Pharma index.The PE of the stock is 20.6 based on TTM earnings ending March 25.Powered by Capital Market - Live

Keytruda, a widely used immunotherapy for various cancer types, recorded global sales of $29.5 billion in 2024. The partnership involves joint development and manufacturing of the biosimilar, with both companies sharing costs and responsibilities. Subject to certain conditions, both parties will also have rights to commercialize the product worldwide. Alvotech, a biotech company focused on biosimilars, already has two approved biosimilars, adalimumab and ustekinumab, marketed in several countries. It has a strong pipeline of nine additional biosimilars and a global network of commercial partnerships spanning the US, Europe, Asia, Latin America, and Africa. Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. On a consolidated basis, net profit of Dr Reddy's Laboratories rose 21.64% to Rs 1593.30 crore while net sales rose 20.09% to Rs 8506 crore in Q4 March 2025 over Q4 March 2024. Powered by Capital Market - Live

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (Alvotech), and Dr. Reddy's Laboratories announced that the companies have entered into a collaboration and license agreement to co develop, manufacture and commercialize a biosimilar candidate to Keytruda' (pembrolizumab) for global markets. Keytruda' (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally.Powered by Capital Market - Live

Dr Reddys Laboratories has allotted 57,840 equity shares of Re.1/- each of the Company, fully paid up, on 03 June 2025, to eligible employees pursuant to exercise of their Stock Options under Dr. Reddy's Employees Stock Options Scheme, 2002.Powered by Capital Market - Live

In a regulatory filing made on Saturday (24 May 2025), the company informed that the US FDA had conducted a GMP inspection at its API manufacturing facility in Miryalaguda, Telangana, India. The inspection was conducted from 19 May 2025 to 24 May 2025. Post the inspection, the American regulatory agency has issued a Form 483 with 2 observations. The pharmaceutical company stated that it would address the said observation from the US FDA within the stipulated timeline. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The company reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year increase from Rs 1,307 crore in the same period last year. Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24. The scrip rose 0.46% to currently trade at Rs 1235.40 on the BSE. Powered by Capital Market - Live

The USFDA completed aforementioned inspection and issued form-483 with two observations. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The company reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year increase from Rs 1,307 crore in the same period last year. Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24. The counter shed 0.35% to end at Rs 1,230.50 on Friday, 16 May 2025.Powered by Capital Market - Live

Dr Reddys Laboratories announced that the United States Food & Drug Administration (USFDA) completed a GMP inspection at its API Middleburgh facility in New York. The inspection was conducted from 12th May, 2025 to 16th May, 2025 (US EST time). The company has been issued a Form 483 with 2 observations. Powered by Capital Market - Live

Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24. On a sequential basis, revenue increased 2% over Rs 8,358.6 crore reported in Q3FY25. Net profit also grew 13% quarter-on-quarter from Rs 1,413.3 crore. EBITDA for the quarter stood at Rs 2,474.9 crore, representing 29.1% of revenue. The board recommended a final dividend of Rs 8 per equity share for the financial year 2024-25. In its global generics business, North America contributed Rs 3,559 crore in revenue, a 9% year-on-year increase. Revenue from Europe rose 145% to Rs 1,275 crore, which includes Rs 597 crore from the newly acquired NRT business. The India business revenue grew 16% YoY to Rs 1,305 crore. The Pharmaceutical Services & Active Ingredients (PSAI) segment reported revenue of Rs 956.3 crore, up 16% year-on-year from Rs 821.9 crore. For the full year FY25, consolidated net profit rose 1.4% to Rs 5,655.10 crore, while net sales increased 16.61% to Rs 32,553.50 crore. Commenting on the results, co-chairman & MD, G V Prasad said: We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S. and the integration of the acquired NRT business. We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Powered by Capital Market - Live

Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24. On a sequential basis, revenue increased 2% over Rs 8,358.6 crore reported in Q3FY25. Net profit also grew 13% quarter-on-quarter from Rs 1,413.3 crore. EBITDA for the quarter stood at Rs 2,474.9 crore, representing 29% of revenue. The board recommended a final dividend of Rs 8 per equity share for the financial year 2024-25. In its global generics business, North America contributed Rs 3,559 crore in revenue, a 9% year-on-year increase. Revenue from Europe rose 145% to Rs 1,275 crore, which includes Rs 597 crore from the newly acquired NRT business. The India business revenue grew 16% YoY to Rs 1,305 crore. The Pharmaceutical Services & Active Ingredients (PSAI) segment reported revenue of Rs 956.3 crore, up 16% year-on-year from Rs 821.9 crore. For the full year FY25, consolidated net profit rose 1.38% to Rs 5,655.1 crore, while net sales increased 16.61% to Rs 32,553.5 crore. Commenting on the results, co-chairman & MD, G V Prasad said: We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S. and the integration of the acquired NRT business. We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth oppportunities. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Powered by Capital Market - Live